(E)-1-<2-<(5-benzyloxy)-4-(1-methylethyl)-2-nitrophenyl>ethenyl>pyrrolidine | 159388-66-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-<2-<(5-benzyloxy)-4-(1-methylethyl)-2-nitrophenyl>ethenyl>pyrrolidine
• 英文别名: 1-[(E)-2-(2-nitro-5-phenylmethoxy-4-propan-2-ylphenyl)ethenyl]pyrrolidine
• CAS: 159388-66-6
• 化学式: C₂₂H₂₆N₂O₃
• 分子量: 366.46
• InChiKey: KYIMDACGGMFRDM-JLHYYAGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-1-<2-<(5-benzyloxy)-4-(1-methylethyl)-2-nitrophenyl>ethenyl>pyrrolidine 在 palladium on activated charcoal 、 镍 氢气 、 一水合肼 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 45.0 ℃ 、172.37 kPa 条件下， 反应 8.5h， 生成 5-hydroxy-6-(1-methylethyl)indole
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of new indole derivatives structurally related to thymoxamine

  摘要：

  The synthesis and pharmacological evaluation of a series of pyrrolidine analogues of thymoxamine allowed access to the basic SAR for the aromatic substitution pattern. The results confirm the relevance of the simultaneous presence of the hydroxy and methyl groups on the benzene ring and prompted us to prepare the corresponding indole congener. The principle of the phenol-indol bioisosterism was confirmed by the results obtained. The introduction of the N-(2 methoxyphenyl)piperazine moiety instead of pyrrolidine changed the receptor affinity profile and introduced a good uroselectivity.

  DOI：

  10.1016/0223-5234(94)90147-3
• 作为产物：
  描述：

  5-甲基-2-(1-甲基乙基)4-硝基苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 (E)-1-<2-<(5-benzyloxy)-4-(1-methylethyl)-2-nitrophenyl>ethenyl>pyrrolidine
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of new indole derivatives structurally related to thymoxamine

  摘要：

  The synthesis and pharmacological evaluation of a series of pyrrolidine analogues of thymoxamine allowed access to the basic SAR for the aromatic substitution pattern. The results confirm the relevance of the simultaneous presence of the hydroxy and methyl groups on the benzene ring and prompted us to prepare the corresponding indole congener. The principle of the phenol-indol bioisosterism was confirmed by the results obtained. The introduction of the N-(2 methoxyphenyl)piperazine moiety instead of pyrrolidine changed the receptor affinity profile and introduced a good uroselectivity.

  DOI：

  10.1016/0223-5234(94)90147-3

文献信息

• Diaminopyrimidines as P2X3 and P2X2/3 antagonists
  申请人：Broka Allen Chris

  公开号：US20050209260A1

  公开（公告）日：2005-09-22

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的治疗化合物和方法，该方法包括向有需要的受试者施用有效量的式I化合物：或其药学上可接受的盐、溶剂化物或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
  申请人：Broka Allen Chris

  公开号：US20070049609A1

  公开（公告）日：2007-03-01

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸系统和胃肠道疾病的方法，包括向有此需要的受试者施用有效量的式(I)化合物：或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• [EN] DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS<br/>[FR] DIAMINOPYRIMIDINES UTILISEES EN TANT QU'ANTAGONISTES DE P2X3 ET P2X2/3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005095359A1

  公开（公告）日：2005-10-13

  Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonists, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

  本发明涉及用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病的化合物和方法，所述方法包括向需要治疗的受体中给予公式（I）的化合物或其药学上可接受的盐、溶剂或前药的有效量，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
  申请人：Broka Chris Allen

  公开号：US20110077242A1

  公开（公告）日：2011-03-31

  Compounds and methods for treating diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  本发明涉及化合物和方法，用于治疗由P2X3和/或P2X2/3受体拮抗剂介导的疾病，其中所述方法包括向需要该治疗的受体中施用化合物I式的有效量，或其药学上可接受的盐、溶剂或前药，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。
• METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES
  申请人：Broka Chris Allen

  公开号：US20120122859A1

  公开（公告）日：2012-05-17

  Methods for treating respiratory and gastrointestinal diseases mediated by a P2X 3 and/or a P2X 2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein.

  治疗由P2X3和/或P2X2/3受体拮抗剂介导的呼吸道和胃肠道疾病的方法，包括向需要治疗的个体施用式(I)的化合物的有效量或其药学上可接受的盐，其中D、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如此定义。